Healthy Clinical Trial
Official title:
Measurement of Total Retinal Blood Flow During Flicker Stimulation in Healthy Subjects
| Verified date | September 2017 |
| Source | Medical University of Vienna |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Neurovascular coupling or functional hyperemia is defined as an essential physiologic
mechanism in the brain, which is necessary for the local adaption of blood flow to altered
metabolic demands of the tissue. It has been shown that also in the eye, blood flow is
considerably coupled to retinal neural activity. The current concept of functional hyperemia
is that visual stimulation, as flicker light, effectuates increasing neural activity in the
retina, which elevates the metabolic needs of the retinal tissue for oxygen and glucose and
consequently induces dilatation and augmented blood flow in the retinal vasculature. In
several studies, stimulation with flicker light has been shown to induce an increase of blood
flow in major retinal arteries and veins as well as an increase of optic nerve head blood
flow. Up until now, flicker induced changes in blood flow were measured solely in the major
retinal arteries and veins with systems such as the commercially available dynamic vessel
analyzer (DVA) by Imedos and with laser Doppler velocimetry (LDV).
In the present study, the investigators propose to measure the response of total retinal
blood flow to diffuse luminance flicker stimulation with bi-directional Fourier Domain
Doppler Optical Coherence Tomography (FDOCT) as well as with Laser Speckle Flowgraphy (LSFG)
in healthy subjects by assessing vessel diameter, blood velocity and blood flow of all
retinal vessels. For comparative reasons, the investigators will furthermore assess the blood
flow of major retinal arteries and veins with the dynamic vessel analyzer (DVA) and laser
Doppler velocimetry (LDV).
| Status | Completed |
| Enrollment | 20 |
| Est. completion date | September 2017 |
| Est. primary completion date | August 2017 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 45 Years |
| Eligibility |
Inclusion Criteria: - Informed consent for participation - Men and women aged between 18 and 45 years - Non-smokers - Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant - Systolic blood pressure < 140 mmHg, diastolic blood pressure < 90 mmHg - Normal ophthalmic findings, ametropia less than 3 diopters Exclusion Criteria: - History or presence of ocular disease - Ametropy = 3 dpt - Treatment with any drug in the 3 weeks preceding the first study day - Symptoms of a clinically relevant illness in the 3 weeks before the first study day - Participation in a clinical trial in the 3 weeks preceding the first study day - Blood donation during the 3 weeks preceding the first study day - History of family history of epilepsy - Abuse of alcoholic beverages - Pregnancy |
| Country | Name | City | State |
|---|---|---|---|
| Austria | Department of Clinical Pharmacology, Medical University of Vienna, Austria | Vienna |
| Lead Sponsor | Collaborator |
|---|---|
| Medical University of Vienna |
Austria,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Flicker induced changes in total retinal blood flow (FDOCT) | 1 day | ||
| Secondary | Red blood cell velocity (LDV) | 1 day | ||
| Secondary | Retinal vessel diameters (DVA) | 1 day | ||
| Secondary | Retinal oxygen saturation (DVA) | 1 day | ||
| Secondary | Relative Flow Volume (LSFG) | 1 day |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |